Cargando…

Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer

BACKGROUND: Epidermal growth factor receptor (EGFR)-mutated lung cancer constitutes a major subgroup of non-small cell lung cancer (NSCLC) and osimertinib is administrated as first-line treatment. However, most patients with osimertinib treatment eventually relapse within one year. The underlying me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Shaocong, Luo, Min, To, Kenneth K. W., Zhang, Jianye, Su, Chaoyue, Zhang, Hong, An, Sainan, Wang, Fang, Chen, Da, Fu, Liwu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812728/ https://www.ncbi.nlm.nih.gov/pubmed/33461557 http://dx.doi.org/10.1186/s12943-021-01307-9

Ejemplares similares

M2‐like macrophage‐derived exosomes facilitate metastasis in non‐small‐cell lung cancer by delivering integrin αVβ3
por: Huang, Lamei, et al.
Publicado: (2022)

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
por: Fu, Kai, et al.
Publicado: (2022)

PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma
por: Luo, Min, et al.
Publicado: (2021)

Exosomes Are Unlikely Involved in Intercellular Nef Transfer
por: Luo, Xiaoyu, et al.
Publicado: (2015)

The key roles of cancer stem cell-derived extracellular vesicles
por: Su, Chaoyue, et al.
Publicado: (2021)

Small but Mighty—Exosomes, Novel Intercellular Messengers in Neurodegeneration
por: Kumari, Meena, et al.
Publicado: (2022)

Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs
por: An, Sainan, et al.
Publicado: (2018)

Exosomes are involved in the intercellular transfer of rapamycin resistance in the breast cancer cells
por: Shchegolev, Yuri Yu., et al.
Publicado: (2023)

Combined targeting of EGFR and BRAF triggers regression of osimertinib resistance by using osimertinib and vemurafenib concurrently in a patient with heterogeneity between different lesions
por: Sun, Mengyao, et al.
Publicado: (2021)

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
por: Leonetti, Alessandro, et al.
Publicado: (2019)

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
por: Fang, Wenfeng, et al.
Publicado: (2019)

Exosomes for Intramyocardial Intercellular Communication
por: Cervio, Elisabetta, et al.
Publicado: (2015)

Exosomes as Intercellular Messengers in Hypertension
por: Arishe, Olufunke Omolola, et al.
Publicado: (2021)

Intercellular Vesicular Transfer by Exosomes, Microparticles and Oncosomes - Implications for Cancer Biology and Treatments
por: Jaiswal, Ritu, et al.
Publicado: (2019)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells
por: Wu, Shaocong, et al.
Publicado: (2018)

ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non‐small cell lung cancer
por: Hou, Helei, et al.
Publicado: (2021)

Treating EGFR mutation resistance in non-small cell lung cancer – role of osimertinib
por: Mazza, Valentina, et al.
Publicado: (2017)

Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
por: Bracht, Jillian Wilhelmina Paulina, et al.
Publicado: (2019)

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
por: Ortega-Franco, Ana, et al.
Publicado: (2022)

Exosome‐derived miR‐210 involved in resistance to osimertinib and epithelial–mesenchymal transition in EGFR mutant non‐small cell lung cancer cells
por: Hisakane, Kakeru, et al.
Publicado: (2021)

Editorial: Synergistic interactions between exosomes and tunneling nanotubes in long-range intercellular transfer
por: Nath, Sangeeta, et al.
Publicado: (2023)

Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer
por: Luo, Min, et al.
Publicado: (2020)

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
por: Uchibori, Ken, et al.
Publicado: (2017)

Inhibition of PLK1 Destabilizes EGFR and Sensitizes EGFR-Mutated Lung Cancer Cells to Small Molecule Inhibitor Osimertinib
por: Eggermont, Carolien, et al.
Publicado: (2023)

Exosomes: secreted vesicles and intercellular communications
por: Théry, Clotilde
Publicado: (2011)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer
por: Zhao, Shen, et al.
Publicado: (2023)

Electron transfer-triggered imaging of EGFR signaling activity
por: Tan, Jie, et al.
Publicado: (2022)

Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib
por: Kunimasa, Kei, et al.
Publicado: (2020)

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
por: Gen, Soei, et al.
Publicado: (2022)

MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer
por: Yan, Dan, et al.
Publicado: (2022)

Intercellular transmission of Seneca Valley virus mediated by exosomes
por: Xu, Guowei, et al.
Publicado: (2020)

EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib
por: Buder, Anna, et al.
Publicado: (2020)

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer
por: Li, Yufeng, et al.
Publicado: (2023)

Exosomes mediate intercellular transfer of non–autonomous tolerance to proteasome inhibitors in mixed‐lineage leukemia
por: Ge, Maolin, et al.
Publicado: (2020)

Dysregulated expression of microRNA involved in resistance to osimertinib in EGFR mutant non-small cell lung cancer cells
por: Zhang, Dianbao, et al.
Publicado: (2023)

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China
por: Shu, Yamin, et al.
Publicado: (2022)

EGFR G796D mutation mediates resistance to osimertinib
por: Zheng, Di, et al.
Publicado: (2017)

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ndksnodnflpd24hnf4o9l0qmo2